AMEX:VNRX

VolitionRx Limited Announces Strategic Acquisition

AUSTIN, Texas, Dec. 16, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH ("Octamer"), for approximately$725,000 consisting of cash and shares of r...

2019-12-16 21:30 13711

VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

AUSTIN, Texas, Dec. 5, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded$820,000 (€740,000 Euros) and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (NASDAQ:MLAB) was awarded$230,000 (€206,000 Euros) each in the form ...

2019-12-05 21:30 11879

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

AUSTIN, Texas, Dec. 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma ("N...

2019-12-03 21:30 11625

VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) ("Volition") today announced it will host a conference call onWednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providin...

2019-11-07 21:30 5983

Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video

AUSTIN, Texas, Oct. 29, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further$500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its sub...

2019-10-29 20:30 6196

Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC

AUSTIN, Texas, Oct. 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated by the previously announced Memorandum of Understanding withTexas A&M University ("Texas A&M"), a memb...

2019-10-26 00:00 8735

Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...

2019-10-18 20:30 10435

Volition Appoints Dr. Phillip Barnes to Board of Directors

AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr.Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effectiveOctober 9, 2019. Dr. Barnes was also appointed to the Company's Audit, C...

2019-10-10 04:05 12398

Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could ...

2019-09-17 20:35 10636

Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expertNathan Dewsbury as its Chief ...

2019-08-08 20:30 7158

VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business upd...

2019-08-07 20:45 7384

Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase$4.8 million in aggregate amount of shares of our common stock...

2019-07-25 04:05 9617

VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platf...

2019-07-18 20:30 12263

VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately$1.4 million from the Walloon Region, Belgium.  To date, Agen...

2019-07-10 20:30 13409

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call onThursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update. ...

2019-05-07 04:05 6881

VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, withTexas A&M University, a member of The Texas A&M University System. Pur...

2019-04-09 20:30 10868

VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering into a ...

2019-03-28 22:48 9691

VolitionRx Limited to Present at Conferences in March & April 2019

ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations,Scott Powell, is scheduled to present at three conferences in March andApril 2019. During the conferences, Dr. Powell will ou...

2019-03-25 20:40 6306

VolitionRx Limited to Present at Conferences in the U.S. Next Week

ISNES, Belgium, March 15, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr.Cameron Reynolds, is scheduled to present at two conferences in the U.S. next week. During the conferences, Mr. Reynolds will outline Volition...

2019-03-15 20:30 5111

VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update

ISNES, Belgium, March 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2018. Volition management will host a conference call tomorrow,March 14, at 8:30a.m. U.S. Eastern...

2019-03-14 04:05 6576

Week's Top Stories